Keynote 054 trial

• Phase III Double blind RCT
  • Pembrolizumab (200mg every 3 weeks, for up to one year) vs placebo
  • 1019 patients
• Indication
  • After resection of stage III disease
• Primary endpoint
  • Recurrence free survival
  • Median F/U 3yrs
• Results
  • 4.9 year follow up date
    • Prolonged recurrence free survival (55 vs 38%)
    • Longer distant metastasis-free survival (60.6% vs. 44.5%)